AI assistant
BeOne Medicines Ltd. — Director's Dealing 2019
Nov 5, 2019
30073_dirs_2019-11-05_7928488b-f7dd-4a5c-94e8-e74e1414551b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2019-11-01
Reporting Person: Wang Xiaodong (Director, Chair, Scientific Advisory Brd)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-11-01 | American Depositary Shares | S | 1000 | $170 | Disposed | 0 | Direct |
| 2019-11-04 | American Depositary Shares | S | 1000 | $190 | Disposed | 0 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 7585628 | Direct |
| Ordinary Shares | 224372 | Indirect |
| Ordinary Shares | 4948000 | Indirect |
Footnotes
F1: These securities are held in a UTMA account for the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.
F2: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.
F3: Each American Depositary Share represents 13 Ordinary Shares.
F4: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.